[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341636-105":59,"doc-detail-341636-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-fatty-acid-oxidation-enhances-response-to-her2-targeted-therapy","Targeting fatty acid oxidation enhances response to HER2-targeted therapy","","Article explores how metabolic reprogramming supports tumor growth, focusing on Carnitine palmitoyl transferase 1a (Cpt1a) in ErbB2-driven breast cancer. In ErbB2+ models, Cpt1a ablation delays tumor onset, growth, and metastasis, while Cpt1a-deficient cells increase glucose dependency and oxidative stress. Nrf2 inhibition or silencing reduces proliferation and glucose consumption. Combining Cpt1a deficiency with a ketogenic diet or anti-ErbB2 monoclonal antibodies perturbs growth, enhances apoptosis, and reduces lung metastasis by reshaping the antitumor immune microenvironment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-fatty-acid-oxidation-enhances-response-to-her2-targeted-therapy/341636/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-fatty-acid-oxidation-enhances-response-to-her2-targeted-therapy/341636.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study’s main target related to fatty acid metabolism?","Question",{"text":113,"@type":114},"The study focuses on Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme for long-chain fatty acid oxidation in ErbB2-driven breast cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does Cpt1a loss affect tumor behavior in ErbB2+ models?",{"text":118,"@type":114},"Cpt1a ablation delays tumor onset, growth, and metastasis, while Cpt1a-deficient cells develop increased glucose dependency that supports survival and eventual progression.",{"name":120,"@type":111,"acceptedAnswer":121},"How do Nrf2 and oxidative stress relate to the Cpt1a-deficient state?",{"text":122,"@type":114},"Cpt1a-deficient cells show heightened oxidative stress and upregulated Nrf2 activity; inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341636,1790630128,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-024-50998-3](https://doi.org/10.1038/s41467-024-50998-3)  \nTargeting fatty acid oxidation enhances response to HER2-targeted therapy  \n\n| Received: 10 January 2024\u003Cbr>Accepted: 23 July 2024\u003Cbr>| Ipshita Nandi1,2, Linjia Ji1, Harvey W. Smith1, Daina Avizonis 1, Vasilios Papavasiliou1,2, Cynthia Lavoie1, Alain Pacis1,3, Sherif Attalla1,2, Virginie Sanguin-Gendreau1,2 & William J. Muller 1,2  |  |\n| --- | --- | --- |\n| | Metabolic reprogramming, a hallmark of tumorigenesis, involves alterations in glucose and fatty acid metabolism. Here, we investigate the role of Carnitinepalmitoyl transferase 1a (Cpt1a), a key enzyme in long-chain fatty acid (LCFA) oxidation, in ErbB2-driven breast cancers. In ErbB2+ breast cancer models, ablation ofCpt1a delays tumor onset, growth, and metastasis. However, Cpt1adeﬁcient cells exhibit increased glucose dependency that enables survival and eventual tumor progression. Consequently, these cells exhibit heightened oxidative stress and upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption in Cpt1a-deﬁcient cells. Combining the ketogenic diet, composed of LCFAs, or an anti-ErbB2 monoclonal antibody (mAb) with Cpt1a deﬁciency signiﬁcantly perturbs tumor growth, enhances apoptosis, and reduces lung metastasis. Using an immunocompetent model, we show that Cpt1a inhibition promotes an antitumor immune microenvironment, thereby enhancing the efﬁcacy of anti-ErbB2 mAbs. Our ﬁndings underscore the importance of targeting fatty acid oxidation alongside HER2-targeted therapies to combat resistance in HER2+ breast cancer patients. |  |\n| Tumorigenesis is dependent on the reprogramming of cellular metabolism as both a direct and an indirect consequence of oncogenic mutations. A deﬁning characteristic of cancer cell metabolism is the ability to acquire nutrients from frequently nutrient-poor environments and utilize these nutrients to sustain viability and support biomass generation1. A markedly increased consumption of glucose by tumors in comparison to non-proliferating cells was ﬁrst described several decades ago by Otto Warburg2. This observation has been conﬁrmed in various cancers and often correlates with poor patient survival3. Glutamine, another principal growth-supporting substrate, contributes not only carbon, but also reduced nitrogen for the de novo biosynthesis of nitrogen-containing compounds such as nucleotides and non-essential amino acids4. The heightened demand for glutamine of proliferating tumor cells was initially described by Harry Eagle in the 1950s, who demonstrated that HeLa cells required 10- to 100-fold molar excess of glutamine in culture relative to other amino acids5. |  | Glutamine depletion from the tumor microenvironment has been associated with various tumorigenic contexts6,7. Altered lipid metabolism, including elevated lipogenesis and fatty acid oxidation (FAO), also plays a signiﬁcant role in breast cancer cells, particularly considering their proximity to adipocytes that create a fatty-acid rich environment8,9. In this context, fatty acids (FAs) are not only consumed for energy production but also act as extrinsic stimuli for cellular growth10–12.\u003Cbr>Carnitine palmitoyl transferase 1 (CPT) is the rate-limiting enzyme facilitating the mitochondrial uptake of long-chain FAs (LCFAs) for FAO13. Three isoforms ofCPT1 have been characterized, CPT1A, CPT1Band CPT1C14. While CPT1B is expressed in skeletal muscles, heart, and adipose tissue, and CPT1C is expressed primarily in the brain, CPT1A has a more widespread pattern of expression15,16. Elevated expression of CPT1A is associated with genetic mutations, metabolic disorders, and several cancers, including breast cancer17. Although high CPT1A |\n\n1Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada. 2Department of Biochemistry, McGill University, Mont","cbCaiduXBZuXdGRv","https://ap.wps.com/l/cbCaiduXBZuXdGRv","pdf",4291571,"English","# Received and Accepted\n# Metabolic reprogramming in cancer\n## Glucose and glutamine dependence\n## Lipid metabolism and fatty acid oxidation\n# Role of CPT1A in long-chain fatty acid oxidation\n## CPT1 isoforms and expression\n# HER2/ErbB signaling and resistance to therapy\n## HER2-targeted treatments\n# Study strategy and key findings\n## Cpt1a ablation in ErbB2-driven models\n## Nrf2 activity and metabolic vulnerabilities\n## Ketogenic diet or anti-ErbB2 mAb with Cpt1a deficiency\n## Antitumor immune microenvironment","[{\"question\":\"What is the study’s main target related to fatty acid metabolism?\",\"answer\":\"The study focuses on Carnitine palmitoyl transferase 1a (Cpt1a), a key enzyme for long-chain fatty acid oxidation in ErbB2-driven breast cancers.\"},{\"question\":\"How does Cpt1a loss affect tumor behavior in ErbB2+ models?\",\"answer\":\"Cpt1a ablation delays tumor onset, growth, and metastasis, while Cpt1a-deficient cells develop increased glucose dependency that supports survival and eventual progression.\"},{\"question\":\"How do Nrf2 and oxidative stress relate to the Cpt1a-deficient state?\",\"answer\":\"Cpt1a-deficient cells show heightened oxidative stress and upregulated Nrf2 activity; inhibiting Nrf2 or silencing its expression reduces proliferation and glucose consumption.\"}]","Targeting fatty acid oxidation enhances response to HER2-targeted therapy | PDF",1790042937,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc1a03a9c336ec8412052ee822749104.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/531759dd2d85b518363f3ec2d69eda2d.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c4160f876429ee7eba5d7253daea4ca.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83445e7576122ae987bc500c40c451b9.webp",980,1301]